Okside-LDL ve reseptörü lektin benzeri okside-LDL reseptör-1

Oksidatif stres fazla oksidant bileşiğin yapılması ve antioksidant koruma mekanizmasının azlığı sonucu oluşarak doku hasarlarına yol açar. Oksidatif stres sonucu oluşan okside-düşük dansiteli lipoprotein (oxidized low-density lipoprotein (ox-LDL)), reseptörü lektin benzeri ox-LDL reseptör-1 (lectin-like receptor for ox-LDL-1 ((LOX-1))'e bağlanır. ox-LDL ve LOX-1 endotel disfonksiyonu, monosit adezyonu, düz kas hücre proliferasyon, migrasyon ve apoptozis, yağ hücre yapımı ve trombosit aktivasyonu ile ilgili mekanizmalarda görev alır. ox-LDL, ateroskleroz, diabetes mellitus, yaşlanma, metabolik sendrom, kardiovasküler, ve serebrovasküler, böbrek ve karaciğer hastalıklarında artarak hastalıkların patogenezlerinde aktif rol alır. Bu derlemede, ox-LDL ve reseptörü LOX-1 etkileri incelenmiştir.

Oxidative stress as a result of excess oxidant compounds and lack of antioxidant protection mechanism may occur and can lead to tissue damage. Oxidized low-density lipoprotein (ox-LDL) caused by oxidative stress binds to lectin-like for receptor ox-LDL receptor-1 (LOX-1). ox-LDL and LOX-1 is involved in endothelial dysfunction, monocyte adhesion, the proliferation, migration, and apoptosis of smooth muscle cells, foam cell formation, platelet activation. ox-LDL increases in atherosclerosis, diabetes, aging, metabolic syndrome, cardiovascular, and cerebrovascular disease kidney and liver and takes an active role in in the pathogenesis of several diseases. In this review, we focused ox-LDL and ıts receptor LOX-1 effects.

PDF

___

1. Itabe H, Ueda M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 2007;14:1-11.

2. Kim HJ, Yuan J, Norris K, Vaziri ND.High-calorie diet partially ameliorates dysregulation of intrarenal lipid metabolism in remnant kidney. J Nutr Biochem 2010; 21:999-1007.

3. Schreurs MP, Cipolla MJ. Cerebrovascular dysfunction and blood-brain barrier permeability induced by oxidized LDL are prevented by apocynin and magnesium sulfate in female rats. J Cardiovasc Pharmacol 2014; 63:33-9.

4. Oteiza A, Li R, McCuskey RS, Smedsrød B, Sørensen KK. Effects of oxidized low-density lipoproteins on the hepatic microvasculature. Am J Physiol Gastrointest Liver Physiol 2011;301:G684-93.

5. Maiolino G, Rossitto G, Caielli P et al. The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm 2013;2013:714653.

6. Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm 2013;2013:152786.

7. Homma Y. Predictors of atherosclerosis. J Atheroscler Thromb 2004;11:265-70.

8. Sakurai K, Sawamura T. Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. J Pharmacol Sci 2003;91:182-6.

9. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001;15:2073-84.

10. Yoshimoto R, Fujita Y, Kakino A et al. The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther 201;25:379-91.

11. Xu S, Ogura S, Chen J et al. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci 2013;70:2859-72.

12. Navarra T, Del Turco S, Berti S, Basta G. The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb 2010;17:317-31.

13. Walenbergh SM, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol 2013;58:801-10.

14. Li R, Oteiza A, Sørensen KK et al. Role of liver sinusoidal endothelial cells and stabilins in elimination of oxidized low-density lipoproteins. Am J Physiol Gastrointest Liver Physiol 2011;300:G71-81.

15. Musso G, Cassader M, De Michieli F et al. Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. Am J Clin Nutr 2011;94:1033-42.

16. Lee HS, Kim YS. Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int 1998;54:848- 56.

17. Itabe H, Yamamoto H, Imanaka T et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996; 37:45-53.

18. Ehara S, Ueda M, Naruko T et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001;103:1955-60.

19. Itabe H, Suzuki K, Tsukamoto Yet al. Lysosomal accumulation of oxidized phosphatidylcholine-apolipoprotein B complex in macrophages: intracellular fate of oxidized low density lipoprotein. Biochim Biophys Acta 2000;1487:233- 45.

20. Gradinaru D, Borsa C, Ionescu C, Margina D. Advanced oxidative andglycoxidative protein damage markers in the elderly with type 2 diabetes. J. Proteomics 2013;92:313-22.

21. Lapointe A, Couillard C, Piche ME et al. Circulating oxidized LDL is associated with parameters of the metabolic syndrome in postmenopausal women. Atherosclerosis 2007 191:362-8.

22. Profumo E, Di Franco M, Buttari B et al. Biomarkers ofsubclinical atherosclerosis in patients with autoimmune disorders. MediatorsInflamm 2012;2012:503942.

23. Besler HT, Comoglu S. Lipoprotein oxidation, plasma total antioxidantcapacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 2003;6:189-96.

24. Dildar K, Sinem F, Gökhan E, Orhan Y, Filiz M. Serum nitrosative stresslevels are increased in Alzheimer disease but not in vascular dementia. Alzheimer Dis. Assoc. Disord 2010;24:194-7.

25. Robman L, McNeil J, Dimitrov P et al. Methodology of the cardiovascularhealth and age-related maculopathy (CHARM) study. Ophthalmic Epidemiol 2004;11:161-79.

26. Mazière C, Savitsky V, Galmiche A et al. Oxidized low density lipoprotein inhibits phosphate signaling andphosphate-induced mineralization in osteoblasts. Involvement of oxidativestress. Biochim Biophys Acta 2010;1802:1013-19.

27. Kankaanpää J, Turunen SP, Moilanen V, Hörkkö S, Remes AM. Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer'sdisease. Neurobiol Dis 2009;33:467-72.

28. Hayashida K, Kume N, Murase T et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome a novel marker for early diagnosis. Circular 2005;112:812-8.

29. Kobayashi N, Takano M, Hata N et al. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a valuable diagnosticmarker for rupture of thin-cap fibroatheroma: verification by opticalcoherence tomography. Int J Cardiol 2013;168: 3217-23.

30. Chen M, Kakutani M, Minami M. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2000;20:1107-15.

31. Nagase M, Hirose S, Sawamura T, Masaki T, Fujita T. Enhanced expression of endothelial oxidized low-density lipoprotein receptor (LOX-1) in hypertensive rats. Biochem Biophys Res Commun 1997;237:496-8.

32. Kume N, Sawamura T, Moriwaki H et al. Inducible expression of LOX-1, a novel lectin-like receptor for oxidized low density lipoprotein, in vascular endothelial cells. Circ Res 1998;83:322-7.

33. Murase T, Kume N, Korenaga R et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 1998;83:328-33.

34. Kataoka H, Miyamoto S. Expression of lectin-like oxidized lowdensity lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999;99:3110-7.

35. Chen M, Nagase M, Fujita T et al. Diabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and age. Biochem Biophys Res Commun 2001;87:962-8.

36. Honjo M, Nakamura K, Yamashiro K et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci U S A 2003;100:1274-9.